Resonance Health Ltd ( (AU:RHT) ) has provided an update.
Resonance Health Ltd announced it received a $473,286 refund from the Australian Taxation Office, which is the net result after accounting for its FY2024 R&D tax incentive and income tax liabilities. This refund will contribute to the company’s cash reserves, as reported in their upcoming financial documents. This development underscores Resonance Health’s ongoing commitment to innovation in healthcare technology and enhances its financial position, potentially benefiting its stakeholders and supporting its strategic growth initiatives.
More about Resonance Health Ltd
Resonance Health is an Australian healthcare technology and services company specializing in providing high-quality quantitative assessments for disease management and drug development. The company has received global endorsements and regulatory clearances for its Software-as-Medical Devices (SaMDs), which incorporate AI technologies, such as FerriScan®, FerriSmart®, HepaFatScan®, HepaFatSmart®, and LiverSmart®. These devices are used for non-invasive assessments of liver iron concentration, liver fat, and heart iron loading, among other applications. Resonance Health also operates in the clinical trial management sector, offering services to global clients.
YTD Price Performance: 6.00%
Average Trading Volume: 376,588
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$24.36M
Find detailed analytics on RHT stock on TipRanks’ Stock Analysis page.